Reported 19 days ago
Novo Nordisk reported better-than-expected sales for its Wegovy weight-loss drug in the third quarter, calming investor fears about declining demand in the competitive obesity drug market. Despite a 48% increase in Wegovy sales compared to the previous quarter, overall sales fell slightly short of analyst expectations due to weaker Ozempic sales, prompting concerns about future growth. The company now forecasts 2024 sales growth between 23% and 27%, reflecting ongoing pricing pressures and investment costs.
Source: YAHOO